Aelis Farma SA (AELIS.PA)
- Previous Close
1.2500 - Open
1.2700 - Bid --
- Ask --
- Day's Range
1.2550 - 1.3550 - 52 Week Range
1.0000 - 13.3000 - Volume
54,872 - Avg. Volume
41,998 - Market Cap (intraday)
17.776M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
www.aelisfarma.comRecent News: AELIS.PA
View MorePerformance Overview: AELIS.PA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AELIS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AELIS.PA
View MoreValuation Measures
Market Cap
17.70M
Enterprise Value
10.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.18
Price/Book (mrq)
1.78
Enterprise Value/Revenue
1.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-134.05%
Return on Assets (ttm)
-21.03%
Return on Equity (ttm)
-63.95%
Revenue (ttm)
5.56M
Net Income Avi to Common (ttm)
-7.46M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
14.05M
Total Debt/Equity (mrq)
60.14%
Levered Free Cash Flow (ttm)
-9.32M